Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2013-02-22 Regulatory Filings
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
EXELIXIS VÄLJER SWEDISH ORPHAN BIOVITRUM AB SOM EUROPEISK DISTRIBUTÖR FÖR COMETRIQ (TM) FÖR MEDULLÄR TYREOIDEACANCER
Regulatory Filings Classification · 95% confidence The document announces a three-year distribution and commercialization agreement between Exelixis and Swedish Orphan Biovitrum (Sobi) for the drug COMETRIQ™ in the EU for a specific cancer indication. It details the terms, responsibilities (regulatory vs. commercial), and payment structures. The text concludes with a statement about the information being made public according to securities market laws, dated February 22, 2013. This type of announcement, detailing a significant business transaction (distribution agreement, partnership), does not fit neatly into the specific financial reporting categories (10-K, ER, IR) or corporate governance filings (DEF 14A, DIRS). It is a general business/regulatory announcement. Since it is a specific business development announcement that isn't explicitly covered by other codes like M&A (TAR) or Capital Change (CAP), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for official regulatory announcements that don't fit elsewhere.
2013-02-22 Swedish
EXELIXIS SELECTS SWEDISH ORPHAN BIOVITRUM AB AS COMETRIQ (TM) EUROPEAN DISTRIBUTOR FOR MEDULLARY THYROID CANCER
Regulatory Filings Classification · 95% confidence The document announces a three-year agreement between Exelixis and Swedish Orphan Biovitrum (Sobi) for the distribution and commercialization of COMETRIQ™ in Europe for Medullary Thyroid Cancer (MTC). It details the terms of the agreement, including regulatory responsibilities, commercialization strategy (starting with Named Patient Use (NPU) and moving to broader sales upon EMA approval), and financial arrangements. This type of announcement, detailing a significant business partnership, financing/distribution agreement, or strategic corporate development, fits best under the Capital/Financing Update (CAP) category, as it directly relates to the commercial structure and revenue generation strategy for a key product. While it is a press release, it is more specific than a general Regulatory Filing (RNS) and does not fit the criteria for an Earnings Release (ER), Interim Report (IR), or a specific legal/governance filing. It is a material business transaction announcement.
2013-02-22 English
Sobis ytterligare emission om 200 Mkr under nuvarande obligationslån fulltecknad
Capital/Financing Update Classification · 99% confidence The document is a short press release (1459 characters) announcing that an additional bond issue ('ytterligare emission om 200 Mkr under nuvarande obligationslån') has been fully subscribed ('fulltecknad'). This directly relates to the company's financing activities and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full report (10-K, IR), an earnings release (ER), or a simple announcement of a report (RPA).
2013-02-21 Swedish
Sobi's additional issuance of SEK 200 million under current bond loan fully subscribed
Capital/Financing Update Classification · 98% confidence The document explicitly announces that Sobi's additional issuance of SEK 200 million under a current bond loan is 'fully subscribed'. This action relates directly to the company's debt structure and fundraising activities. Based on the provided definitions, this fits best under 'Capital/Financing Update' (Code: CAP), which covers updates on company fundraising and capital structure changes. The document is short and is an announcement, not a comprehensive report, confirming it is an event-based filing.
2013-02-21 English
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the fourth quarter and full year 2012 for the company Sobi. It contains detailed financial statements, including income statements, revenue breakdowns by product and region, cash flow analysis, and management commentary on business performance. It is not a short announcement or a certification, but the actual interim/quarterly report itself, which fits the definition of an Interim / Quarterly Report (IR). Q4 2012
2013-02-21 Swedish
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the fourth quarter and full year 2012, containing detailed financial statements, revenue breakdowns, operating profit/loss, and management commentary. It is not merely an announcement or a summary, but the actual interim/quarterly report itself, fitting the definition of an Interim / Quarterly Report (IR). Q4 2012
2013-02-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.